Hydroxyurea is associated with reduction of hypercoagulability markers in sickle cell anemia
Journal of Thrombosis and Haemostasis, 08/09/2012
Colella MP et al. – Hydroxyurea (hydroxycarbamide) is currently one of the main pillars of sickle cell anemia (SCA) management, improving both clinical complications and mortality in SCA and has several well–defined beneficial effects that could contribute to an inhibition of the hypercoagulability state in SCA. These include a reduction of phosphatidylserine exposure by erythrocytes, reduction of adhesive properties of erythrocytes and leukocytes, endothelial activation, nitric oxide depletion, platelet activation and adhesive properties.